flecainide has been researched along with Extrasystole, Ventricular in 24 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The cardiac safety of a once-a-day 200 mg controlled-release formulation of flecainide acetate in the prevention of paroxysmal atrial fibrillation (PAF) was assessed in outpatients." | 7.72 | Safety of a controlled-release flecainide acetate formulation in the prevention of paroxysmal atrial fibrillation in outpatients. ( Aliot, E; Capucci, A; Coumel, P; De Roy, L; Denjoy, I; Hernández, J; Lupoglazoff, JM, 2003) |
| "The cardiac safety of a once-a-day 200 mg controlled-release formulation of flecainide acetate in the prevention of paroxysmal atrial fibrillation (PAF) was assessed in outpatients." | 3.72 | Safety of a controlled-release flecainide acetate formulation in the prevention of paroxysmal atrial fibrillation in outpatients. ( Aliot, E; Capucci, A; Coumel, P; De Roy, L; Denjoy, I; Hernández, J; Lupoglazoff, JM, 2003) |
| "The test may also induce premature ventricular complexes (PVCs) in individuals without Brugada pattern, the clinical relevance of which is little known." | 2.82 | Malignant Purkinje ectopy induced by sodium channel blockers. ( Bernus, O; Cheniti, G; Combes, N; Derval, N; Duchateau, J; Escande, W; Gandjbakhch, E; Gourraud, JB; Haissaguerre, M; Hermida, JS; Hocini, M; Jaïs, P; Krisai, P; Lavergne, T; Martins, R; Maury, P; Merino, JL; Nademanee, K; Pambrun, T; Pasquié, JL; Postema, PG; Probst, V; Sacher, F; Surget, E; Vigmond, E, 2022) |
| "This multicenter study suggests that oral flecainide therapy is an effective and safe means of suppressing VAs in patients with ATS with KCNJ2 mutations, though the U-wave amplitude remained unchanged by flecainide." | 2.80 | Efficacy and safety of flecainide for ventricular arrhythmias in patients with Andersen-Tawil syndrome with KCNJ2 mutations. ( Aiba, T; Anzai, T; Hayashi, H; Horie, M; Ishibashi, K; Ishihara, M; Kamakura, S; Kimura, H; Kusano, K; Miyamoto, K; Miyamoto, Y; Nakajima, I; Noda, T; Ogawa, H; Ohno, S; Okamura, H; Shimizu, W; Tanioka, Y; Tsuboi, I; Tsuchiya, T; Yasuda, S; Yasuoka, C; Yoshida, Y, 2015) |
| "Flecainide was the most effective AAD in the achievement of complete/near complete or significant PVC burden reduction, compared to propafenone and sotalol." | 1.91 | Idiopathic premature ventricular complexes treatment: Comparison of flecainide, propafenone, and sotalol. ( Bukumirić, Z; Jurčević, R; Kojić, D; Marić, M; Radunović, A; Rajsic, S; Sušić, M; Tomović, M; Žugić, V, 2023) |
| " A medication episode was defined as a timeframe in which the highest dosage at a fixed level of a single drug was used in a patient." | 1.62 | The Efficacy of Anti-Arrhythmic Drugs in Children With Idiopathic Frequent Symptomatic or Asymptomatic Premature Ventricular Complexes With or Without Asymptomatic Ventricular Tachycardia: a Retrospective Multi-Center Study. ( Bertels, RA; Blom, NA; Filippini, LH; Kammeraad, JAE; Knobbe, I; Kuipers, IM; Zeelenberg, AM, 2021) |
| "The flecainide treatment significantly reduced the frequency of PVCs during and after exercise." | 1.43 | Antiarrhythmic Action of Flecainide in Polymorphic Ventricular Arrhythmias Caused by a Gain-of-Function Mutation in the Nav 1.5 Sodium Channel. ( Abriel, H; Amarouch, MY; Kontula, K; Lahtinen, AM; Leinonen, J; Marjamaa, A; Swan, H; Toivonen, L; Widen, E, 2016) |
| "Flecainide testing was performed at each follow-up visits ≤6 months." | 1.42 | Brugada Syndrome Phenotype Elimination by Epicardial Substrate Ablation. ( Berruezo, A; Brugada, J; Ciconte, G; Giannelli, L; Manguso, F; Pappone, C; Santinelli, V; Vicedomini, G, 2015) |
| "Control animals developed premature ventricular complexes (PVCs) followed by ventricular tachycardia, which terminated in VF in 5 of the 8 dogs." | 1.39 | HBI-3000 prevents secondary sudden cardiac death. ( Lee, JY; Lucchesi, BR, 2013) |
| "Flecainide acetate has a relatively long blood elimination half-life and a narrow safety margin." | 1.30 | [Benefit of monitoring the level of blood flecainide acetate in an elderly patient with ventricular premature contractions]. ( Chiba, K; Kaku, T; Nagashima, J; Ueda, K, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (12.50) | 18.2507 |
| 2000's | 4 (16.67) | 29.6817 |
| 2010's | 12 (50.00) | 24.3611 |
| 2020's | 5 (20.83) | 2.80 |
| Authors | Studies |
|---|---|
| Rosenthal, DG | 1 |
| Lee, BK | 1 |
| Scheinman, MM | 1 |
| Escande, W | 1 |
| Gourraud, JB | 1 |
| Haissaguerre, M | 1 |
| Gandjbakhch, E | 1 |
| Lavergne, T | 1 |
| Martins, R | 1 |
| Cheniti, G | 1 |
| Krisai, P | 1 |
| Hermida, JS | 1 |
| Maury, P | 1 |
| Merino, JL | 1 |
| Pasquié, JL | 1 |
| Combes, N | 1 |
| Surget, E | 1 |
| Duchateau, J | 1 |
| Pambrun, T | 1 |
| Derval, N | 1 |
| Hocini, M | 1 |
| Jaïs, P | 1 |
| Postema, PG | 1 |
| Nademanee, K | 1 |
| Vigmond, E | 1 |
| Bernus, O | 1 |
| Sacher, F | 1 |
| Probst, V | 1 |
| Ebrahim, MA | 1 |
| Alkhabbaz, AA | 1 |
| Albash, B | 1 |
| AlSayegh, AH | 1 |
| Webster, G | 1 |
| Kojić, D | 1 |
| Radunović, A | 1 |
| Bukumirić, Z | 1 |
| Rajsic, S | 1 |
| Sušić, M | 1 |
| Marić, M | 1 |
| Žugić, V | 1 |
| Jurčević, R | 1 |
| Tomović, M | 1 |
| Bertels, RA | 1 |
| Kammeraad, JAE | 1 |
| Zeelenberg, AM | 1 |
| Filippini, LH | 1 |
| Knobbe, I | 1 |
| Kuipers, IM | 1 |
| Blom, NA | 2 |
| Hyman, MC | 1 |
| Mustin, D | 1 |
| Supple, G | 1 |
| Schaller, RD | 1 |
| Santangeli, P | 1 |
| Arkles, J | 1 |
| Lin, D | 1 |
| Muser, D | 1 |
| Dixit, S | 1 |
| Nazarian, S | 1 |
| Epstein, AE | 1 |
| Callans, DJ | 1 |
| Marchlinski, FE | 1 |
| Frankel, DS | 2 |
| Capucci, A | 2 |
| Ciliberti, G | 1 |
| Guerra, F | 1 |
| Osadchii, OE | 1 |
| Wellens, HJ | 1 |
| Sato, A | 1 |
| Takano, T | 1 |
| Chinushi, M | 1 |
| Minamino, T | 1 |
| Lee, JY | 1 |
| Lucchesi, BR | 1 |
| Janson, CM | 1 |
| Poelzing, S | 1 |
| Shah, MJ | 1 |
| Miyamoto, K | 1 |
| Aiba, T | 1 |
| Kimura, H | 1 |
| Hayashi, H | 2 |
| Ohno, S | 1 |
| Yasuoka, C | 1 |
| Tanioka, Y | 1 |
| Tsuchiya, T | 1 |
| Yoshida, Y | 1 |
| Tsuboi, I | 1 |
| Nakajima, I | 1 |
| Ishibashi, K | 1 |
| Okamura, H | 1 |
| Noda, T | 1 |
| Ishihara, M | 1 |
| Anzai, T | 1 |
| Yasuda, S | 1 |
| Miyamoto, Y | 1 |
| Kamakura, S | 1 |
| Kusano, K | 1 |
| Ogawa, H | 1 |
| Horie, M | 1 |
| Shimizu, W | 1 |
| Brugada, J | 1 |
| Pappone, C | 1 |
| Berruezo, A | 1 |
| Vicedomini, G | 1 |
| Manguso, F | 1 |
| Ciconte, G | 1 |
| Giannelli, L | 1 |
| Santinelli, V | 1 |
| Amarouch, MY | 1 |
| Swan, H | 1 |
| Leinonen, J | 1 |
| Marjamaa, A | 1 |
| Lahtinen, AM | 1 |
| Kontula, K | 1 |
| Toivonen, L | 1 |
| Widen, E | 1 |
| Abriel, H | 1 |
| Fox, DJ | 1 |
| Klein, GJ | 1 |
| Hahn, A | 1 |
| Skanes, AC | 1 |
| Gula, LJ | 1 |
| Yee, RK | 1 |
| Subbiah, RN | 1 |
| Krahn, AD | 1 |
| Lim, HS | 1 |
| Kuchar, D | 1 |
| Walker, B | 1 |
| Thorburn, C | 1 |
| Subbiah, R | 1 |
| Aliot, E | 1 |
| De Roy, L | 1 |
| Hernández, J | 1 |
| Denjoy, I | 1 |
| Lupoglazoff, JM | 1 |
| Coumel, P | 1 |
| Morady, F | 1 |
| Bökenkamp, R | 1 |
| Wilde, AA | 1 |
| Schalij, MJ | 1 |
| Kellen, JC | 1 |
| Ettinger, A | 1 |
| Todd, L | 1 |
| Brezsnyak, ML | 1 |
| Campion, J | 1 |
| McBride, R | 1 |
| Thomas, S | 1 |
| Corum, J | 1 |
| Schron, E | 1 |
| Anderson, JL | 1 |
| Pratt, CM | 1 |
| Waldo, AL | 1 |
| Karagounis, LA | 1 |
| Nagashima, J | 1 |
| Kaku, T | 1 |
| Chiba, K | 1 |
| Ueda, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Electrical Substrate Elimination in Brugada Syndrome. Results in 135 Consecutive Patients[NCT02641431] | 135 participants (Actual) | Interventional | 2015-11-16 | Completed | |||
| [NCT00000526] | Phase 3 | 0 participants | Interventional | 1986-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for flecainide and Extrasystole, Ventricular
| Article | Year |
|---|---|
Malignant Purkinje ectopy induced by sodium channel blockers.
Topics: Adult; Ajmaline; Catheter Ablation; Electrocardiography; Flecainide; Humans; Male; Middle Aged; Repr | 2022 |
2 trials available for flecainide and Extrasystole, Ventricular
| Article | Year |
|---|---|
Efficacy and safety of flecainide for ventricular arrhythmias in patients with Andersen-Tawil syndrome with KCNJ2 mutations.
Topics: Administration, Oral; Adolescent; Adult; Andersen Syndrome; Anti-Arrhythmia Agents; Electrocardiogra | 2015 |
The Cardiac Arrhythmia Suppression Trial: Implications for nursing practice.
Topics: Aged; Anti-Arrhythmia Agents; Critical Care; Death, Sudden, Cardiac; Encainide; Female; Flecainide; | 1996 |
21 other studies available for flecainide and Extrasystole, Ventricular
| Article | Year |
|---|---|
Incessant multiform ectopy in a young woman: What is the mechanism and treatment?
Topics: Adult; Anti-Arrhythmia Agents; Atrial Premature Complexes; Bundle-Branch Block; Echocardiography; El | 2021 |
Trans-2,3-enoyl-CoA reductase-like-related catecholaminergic polymorphic ventricular tachycardia with regular ventricular tachycardia and response to flecainide.
Topics: Anti-Arrhythmia Agents; Flecainide; Humans; Oxidoreductases; Ryanodine Receptor Calcium Release Chan | 2023 |
Idiopathic premature ventricular complexes treatment: Comparison of flecainide, propafenone, and sotalol.
Topics: Anti-Arrhythmia Agents; Electrocardiography; Flecainide; Humans; Propafenone; Retrospective Studies; | 2023 |
The Efficacy of Anti-Arrhythmic Drugs in Children With Idiopathic Frequent Symptomatic or Asymptomatic Premature Ventricular Complexes With or Without Asymptomatic Ventricular Tachycardia: a Retrospective Multi-Center Study.
Topics: Adolescent; Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Child; Child, Preschool; Female; Fl | 2021 |
Class IC antiarrhythmic drugs for suspected premature ventricular contraction-induced cardiomyopathy.
Topics: Anti-Arrhythmia Agents; Cardiomyopathies; Echocardiography; Electrocardiography; Female; Flecainide; | 2018 |
Reply to the Editor- Flecainide and Propafenone: Good twins for premature ventricular contractions' killing but not exactly superimposable.
Topics: Anti-Arrhythmia Agents; Electrocardiography; Flecainide; Humans; Propafenone; Ventricular Premature | 2018 |
To the Editor- Flecainide and propafenone: Good twins for premature ventricular contractions' killing but not exactly superimposable.
Topics: Anti-Arrhythmia Agents; Cardiomyopathies; Flecainide; Humans; Propafenone; Ventricular Premature Com | 2018 |
Determinants of slowed conduction in premature ventricular beats induced during programmed stimulations in perfused guinea-pig heart.
Topics: Action Potentials; Animals; Electric Stimulation; Flecainide; Guinea Pigs; Heart; Heart Conduction S | 2018 |
Two different P waves after a single ventricular premature beat in a 33-year-old man.
Topics: Adult; Anti-Arrhythmia Agents; Atrioventricular Node; Electrocardiography; Flecainide; Heart Rate; H | 2018 |
Usefulness of the intravenous flecainide challenge test before oral flecainide treatment in a patient with Andersen-Tawil syndrome.
Topics: Administration, Intravenous; Administration, Oral; Adult; Andersen Syndrome; Anti-Arrhythmia Agents; | 2019 |
HBI-3000 prevents secondary sudden cardiac death.
Topics: Animals; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Disease Models, Animal; Dogs; Dose-Response | 2013 |
Combined inhibition of Na⁺ and Ca²⁺ channels: a novel paradigm for the treatment of incessant ventricular arrhythmias in Andersen-Tawil syndrome.
Topics: Adolescent; Andersen Syndrome; Arrhythmias, Cardiac; Calcium Channel Blockers; Electrocardiography, | 2014 |
Brugada Syndrome Phenotype Elimination by Epicardial Substrate Ablation.
Topics: Action Potentials; Adult; Anti-Arrhythmia Agents; Brugada Syndrome; Catheter Ablation; Death, Sudden | 2015 |
Antiarrhythmic Action of Flecainide in Polymorphic Ventricular Arrhythmias Caused by a Gain-of-Function Mutation in the Nav 1.5 Sodium Channel.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Electrocardiography; Exercise Test; Female; Flecainide; HEK293 | 2016 |
Reduction of complex ventricular ectopy and improvement in exercise capacity with flecainide therapy in Andersen-Tawil syndrome.
Topics: Anti-Arrhythmia Agents; Drug Therapy, Combination; Exercise Test; Exercise Tolerance; Flecainide; Gl | 2008 |
Incessant tachycardia following posteroseptal pathway ablation: a pseudo-r' or pseudo-pseudo-r' wave in V1?
Topics: Accessory Atrioventricular Bundle; Adult; Catheter Ablation; Digoxin; Electrocardiography; Flecainid | 2010 |
Safety of a controlled-release flecainide acetate formulation in the prevention of paroxysmal atrial fibrillation in outpatients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Delayed-Ac | 2003 |
Wide QRS complexes during atrial fibrillation: what is the mechanism?
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electrophysiology; Flecainide; Humans; Male; Middle Age | 2004 |
Flecainide for recurrent malignant ventricular arrhythmias in two siblings with Andersen-Tawil syndrome.
Topics: Andersen Syndrome; Anti-Arrhythmia Agents; Child; Child, Preschool; Defibrillators, Implantable; Fem | 2007 |
Impact of the Food and Drug Administration approval of flecainide and encainide on coronary artery disease mortality: putting "Deadly Medicine" to the test.
Topics: Anti-Arrhythmia Agents; Coronary Disease; Drug Approval; Drug Utilization; Encainide; Evaluation Stu | 1997 |
[Benefit of monitoring the level of blood flecainide acetate in an elderly patient with ventricular premature contractions].
Topics: Aged; Anti-Arrhythmia Agents; Drug Monitoring; Electrocardiography; Female; Flecainide; Humans; Vent | 1997 |